{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.6","upperLimit":"84.6","value":"79.7"},{"groupId":"OG001","lowerLimit":"74.7","upperLimit":"85.4","value":"80.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"PFS rate was defined as the percentage of participants without disease progression or death due to any cause at 12 months. The PFS rate at 12 months was estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 95% CIs were estimated using the method by Kalbfleisch and Prentice (1980). PFS data was censored for participants who met any one of the following: 1. no baseline/no post-baseline disease assessments; 2. starting new anti-myeloma therapy before documentation of progressive disease (PD) or death; 3. PD or death immediately after more than 1 consecutively missed disease assessment visit (PD or death immediately after \\> 63 days without disease assessment visit); 4. alive without documentation of PD; 5. lost to follow-up or withdrawn consent.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"paramType":"NUMBER","populationDescription":"The ITT analysis set included all randomized participants.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Kaplan-Meier Estimate of Progression-free Survival (PFS) Rate at 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}